## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Darteil et al.

Examiner:

Art Unit:

Serial No.: 10/018,729

Filed:

**December 18, 2001** 

Title:

SYSTEM FOR REGULATION OF **EXPRESSION USING PPAR** 

**NUCLEAR RECEPTORS** 

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioger for Patents, Washington, D.C. 20231, on

## REPLY TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION FILED UNDER 37 C.F.R. 1.53(b)

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the "NOTIFICATION OF MISSING PARTS" which was mailed on February 22, 2002 and which indicated that the oath or declaration was missing, Applicants submit herewith the Declaration for the present application, and a copy of the Notice.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,

01.E5/E002 RRLI11 00000031 181982

10018729


00 FD:154

130.00 CH

William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-4854 Telefax (908) 231-2626

Docket No. ST99021 US PCT April 22, 2002



Date Mailed: 02/22/2002

# NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- · U.S. Basic National Fees
- Priority Document
- · Biochemical Sequence Listing
- · Copy of IPE Report
- Copy of references cited in ISR
- . Copy of the International Application
- . Copy of the International Search Report
- · Oath or Declaration

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
  - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- \$130 Surcharge for providing the oath or declaration later than the appropriate 30 months months from the priority date (37 CFR 1.492(e)) is required.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions



of 37 CFR 1.136(a).

Additionally the following defects have been observed:

.

The following items MUST be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
  - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
  - APPLICANT MUST PROVIDE:
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
    - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
    - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
  - Additional claim fees of \$36 as a non-small entity, including any required multiple dependent claim fee, are
    required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are
    due.

### SUMMARY OF FEES DUE:

Total additional fees required for this application is \$166 for a Large Entity:

- \$130 Late oath or declaration Surcharge.
- Total additional claim fee(s) for this application is \$36
  - \$36 for 17 total claims over 20.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

### BARBARA A CAMPBELL

Telephone: (703) 305-3631

### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/018,729	PCT/FR00/01744	ST99021 US PCT

FORM PCT/DO/EO/905 (371 Formalities Notice)